Company Profile

Palatin Technologies Inc (AKA: RhoMed Inc)
Profile last edited on: 7/16/2023      CAGE: 5C0P2      UEI: S8GVN3GVSUV6

Business Identifier: Novel therapeutics for those living with inflammatory and autoimmune conditions
Year Founded
1986
First Award
1986
Latest Award
2002
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

4-B Cedar Brook Drive
Cranbury, NJ 08512
   (609) 495-2200
   info@palatin.com
   www.palatin.com
Location: Multiple
Congr. District: 12
County: Middlesx

Public Profile

Palatin Technologies, Inc. (NYSE:PTN) is a US based biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of various diseases. Very active in SBIR in the firm's early years (1986-2022) but not recently, the company's lead product is Bremelanotide, an as needed subcutaneous injectable peptide melanocortin receptor agonist currently in the Phase III clinical studies for the treatment of premenopausal women with hypoactive sexual desire disorder (HSDD). The firm's drug development programs also include Melanocortin receptor-4 (MC4r) peptides and small molecule agonists that are under the preclinical trials for the treatment of conditions responsive to MC4r activation, including female sexual dysfunction, HSDD, erectile dysfunction, obesity, and diabetes; and Melanocortin receptor-1 peptide agonists, which are under preclinical studies for the treatment of inflammatory and dermatologic disease indications, as well as other Melanocortin receptors. In addition, the company is involved in the development of natriuretic peptide receptor-specific programs, including PL-3994, a natriuretic peptide receptor-A, which is in Phase II clinical studies for treatment of heart failure, acute exacerbations of asthma, and refractory hypertension.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
25-49
Revenue Range
2.5M-5M
VC funded?
Yes
Public/Private
Publicly Traded
Stock Info
NYSE : PTN
IP Holdings
100-149

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2002 2 NIH $810,960
Project Title: Imaging Thromboembolism with TC-99m-Peptide, TP1201
2000 2 NIH $843,946
Project Title: Novel 99MTC-Tuftsin For Imaging Inflammation Foci
2000 1 NIH $92,865
Project Title: Melanocortin Receptor-1 Specific 99mtc-Metallopeptides
1999 1 NIH $113,250
Project Title: Melanocortin-4 Receptor Specific Metallopeptide Analog
1999 1 NIH $148,409
Project Title: Intranasal Delivery Of Novel Peptide Therapeutics

Key People / Management

  Carl Spana -- President and CEO

  Christine H Blood

  Jeffrey D Edelson -- Chief Medical Officer

  Trevor Hallam -- Executive Vice President of Research & Development

  Aru Ma'Ayan

  Michael Raizman -- Chief Medical Officer

  Buck A Rhodes

  Shubh D Sharma -- Vice President and Chief Scientific Officer

  Stephen Slusher -- Chief Legal Officer

  Terry D Smith

  Mathew L Thakur

  Stephen T Wills -- Chief Financial Officer and Executive Vice President - Operations